71 related articles for article (PubMed ID: 7803707)
1. Development of a nude mouse model of ras-mediated neoplasia using WR21 cells from a transgenic mouse salivary tumor.
Nielsen LL; Gurnani M; Porter G; Trexler S; Emerson D; Tyler RD
In Vivo; 1994; 8(3):295-302. PubMed ID: 7803707
[TBL] [Abstract][Full Text] [Related]
2. Strategy for developing transgenic assays for screening antineoplastic drugs that affect tubulin polymerization.
Porter GM; Armstrong L; Nielsen LL
Lab Anim Sci; 1995 Apr; 45(2):145-50. PubMed ID: 7603014
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs.
Nielsen LL; Gurnani M; Tyler RD
Cancer Res; 1992 Jul; 52(13):3733-8. PubMed ID: 1617645
[TBL] [Abstract][Full Text] [Related]
4. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene.
Nielsen LL; Discafani CM; Gurnani M; Tyler RD
Cancer Res; 1991 Jul; 51(14):3762-7. PubMed ID: 2065330
[TBL] [Abstract][Full Text] [Related]
5. In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background.
Nielsen LL; Gurnani M; Catino JJ; Tyler RD
Anticancer Res; 1995; 15(2):385-92. PubMed ID: 7763010
[TBL] [Abstract][Full Text] [Related]
6. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
7. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model.
Adnane J; Jackson RJ; Nicosia SV; Cantor AB; Pledger WJ; Sebti SM
Oncogene; 2000 Nov; 19(47):5338-47. PubMed ID: 11103935
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a nude mouse tumor model using beta-galactosidase-expressing melanoma cells.
Dooley TP; Stamp-Cole M; Ouding RJ
Lab Anim Sci; 1993 Feb; 43(1):48-57. PubMed ID: 7681492
[TBL] [Abstract][Full Text] [Related]
10. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma.
Liu X; Lee J; Cooley M; Bhogte E; Hartley S; Glick A
Cancer Res; 2003 Nov; 63(22):7760-8. PubMed ID: 14633701
[TBL] [Abstract][Full Text] [Related]
11. Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and gastrointestinal tract neoplasms.
Schaffner DL; Barrios R; Shaker MR; Rajagopalan S; Huang SL; Tindall DJ; Young CY; Overbeek PA; Lebovitz RM; Lieberman MW
Lab Invest; 1995 Mar; 72(3):283-90. PubMed ID: 7534850
[TBL] [Abstract][Full Text] [Related]
12. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
[TBL] [Abstract][Full Text] [Related]
13. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo.
Nakashiro K; Kawamata H; Hino S; Uchida D; Miwa Y; Hamano H; Omotehara F; Yoshida H; Sato M
Cancer Res; 1998 Feb; 58(3):549-55. PubMed ID: 9458104
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced Ha-ras oncogene products.
Caulín C; López-Barcons L; Gonzáles-Garrigues M; Navarro P; Lozano E; Rodrigo I; Gamallo C; Cano A; Fabra A; Quintanilla M
Mol Carcinog; 1996 Feb; 15(2):104-14. PubMed ID: 8599577
[TBL] [Abstract][Full Text] [Related]
16. A transgenic mouse model for mammary carcinogenesis.
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM
Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874
[TBL] [Abstract][Full Text] [Related]
17. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas.
Ding H; Roncari L; Shannon P; Wu X; Lau N; Karaskova J; Gutmann DH; Squire JA; Nagy A; Guha A
Cancer Res; 2001 May; 61(9):3826-36. PubMed ID: 11325859
[TBL] [Abstract][Full Text] [Related]
18. Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression.
Declercq J; Van Dyck F; Braem CV; Van Valckenborgh IC; Voz M; Wassef M; Schoonjans L; Van Damme B; Fiette L; Van de Ven WJ
Cancer Res; 2005 Jun; 65(11):4544-53. PubMed ID: 15930271
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V).
Pavlovic J; Nawrath M; Tu R; Heinicke T; Moelling K
Gene Ther; 1996 Jul; 3(7):635-43. PubMed ID: 8818652
[TBL] [Abstract][Full Text] [Related]
20. [Development of salivary gland tumors in pleomorphic adenoma gene 1 transgenic mice].
Zhao XD; Yang WJ; Wang L; Kong H; Ren WH; Zhang M; Fei J; Zhang CP; Wang ZG
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Oct; 20(5):390-5. PubMed ID: 14556190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
